Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @SilasInman, LinkedIn, sinman@mjhlifesciences.com.

Articles

Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL

December 12th 2017

Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Acalabrutinib Highly Effective for Refractory MCL

December 11th 2017

Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.

Axi-Cel Responses Sustained With Longer Follow-Up for NHL

December 10th 2017

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

Ibrutinib/Venetoclax Combo Impresses in Early CLL Data

December 10th 2017

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

December 9th 2017

The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.

Pembrolizumab/Eribulin Efficacy Maintained for TNBC in Larger Dataset

December 9th 2017

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

Neoadjuvant Abemaciclib Active in Early Breast Cancer

December 8th 2017

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

Nab-Paclitaxel Shows Greatest Utility for TNBC

December 8th 2017

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

Frontline Atezolizumab Regimen Improves PFS in NSCLC

December 7th 2017

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Sacituzumab Govitecan Highly Effective in Heavily Pretreated mTNBC

December 6th 2017

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC

November 20th 2017

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

November 18th 2017

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy

November 17th 2017

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

Novel Combination Shows Promising Responses in Pancreatic Cancer

November 12th 2017

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

JCAR015 Experience Informs Future CAR-T Studies

November 11th 2017

The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.

Combinations Required to Further Advance Adoptive T-Cell Therapy

November 10th 2017

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

FDA Approves Letermovir for CMV Prophylaxis Post-Transplantation

November 9th 2017

The FDA has approved letermovir to prevent cytomegalovirus infection and disease in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant.

FDA Approves Vemurafenib for Rare Blood Cancer

November 6th 2017

The FDA has approved vemurafenib as a treatment for patients with Erdheim-Chester disease.